**Anti-obesity Drugs Market to Reach USD 3,421.0 Million by 2027; Increasing Adoption of Weight Management Drugs to Aid Growth, states Fortune Business Insights™ ** The global anti-obesity drugs market size is set to grow significantly owing to the ever-increasing prevalence of obesity among the global population, observes Fortune Business Insights™ in its report, titled, “Anti-obesity Drugs Market Size, Share & COVID-19 Impact Analysis, By Type (Prescription Drugs and OTC Drugs), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size was USD 1,520.2 million in 2019 and is anticipated to reach USD 3,421.0 million by 2027, exhibiting a CAGR of 10.1% during the forecast period. Request Sample PDF@ Request a Sample - Anti-obesity Drugs Market Size, Share and Global Industry Trend Forecast till 2025 (https://www.fortunebusinessinsights.com/enquiry/sample/anti-obesity-drugs-market-104783) Healthcare Sector to Stumble amid COVID-19 Pandemic The healthcare sector has been the most active ever since the COVID-19 outbreak. While the pandemic has fast-tracked the development of the industry on a global scale, it has also brought numerous adversities upon the sector. These adversities include limited infrastructure in developing countries and the lack of preparedness in case of health emergencies. Key players are focusing on eliminating such challenges. ***Industry Developments-*** · **In December 2020, **theU.S. Food and Drug Administration (FDA) approved Saxenda, Novo Nordisk’s anti-obesity drug for the treatment of obesity in adolescents aged 12-17. · **In February 2019, **Eisai Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted its new supplemental drug application. This will update the labeling of BELVIQ, the company’s anti-obesity drug. ***A List of Key Manufacturers Operating In the Market Report:*** • Novo Nordisk (Denmark, Scandinavia) • GlaxoSmithKline (Brentford, U.K) • Vivus Pharmaceuticals (California U.S) • Currax Pharmaceuticals LLC (New Jersey, U.S) • Pfizer Inc. (New York, U.S) • F. Hoffmann-La Roche Ltd (Basel, Switzerland) • Other Players